Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

Prof. Pollard preparing to deliver coronavirus vaccinations at the Kassam Stadium © Oxford Health NHS Foundation Trust

The first such large scale centre to be set up by Oxford Health NHS Foundation Trust, the Kassam Stadium, home to the city’s League One football side, will be open to the public by invite-only, seven days a week, from 8am to 8pm, as part of the national effort to vaccinate against COVID-19.  

Prof. Pollard said:  

‘To see a vaccination centre in Oxford delivering the vaccine that was developed in the city is a great moment. So much hard work has gone into getting to this stage from the researchers developing the vaccine and the Oxford Health team making all the arrangements to set up and run an efficient vaccination centre. Many volunteers from Oxfordshire took part in the clinical trials and it is a huge credit to their commitment that we can benefit from this vaccine today. 

‘We anticipate that the vaccination of as many people as possible as soon as possible will start to have a big impact on hospitalisations and is something everyone has been hoping for. However, vaccination is only one part of the story - people should continue to follow public health measures, such as observing the rules of lockdown, social distancing, wearing masks and washing their hands until we get the virus back under control.’ 

Read the full story on the University of Oxford website

Similar stories

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.